IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

(Scan this QR Code to View the RHP)

This is an abridged prospectus containing salient features of the Red Herring Prospectus dated December 26, 2024 (the "RHP"). You are encouraged to read greater details available in the RHP, this abridged prospectus ("Abridged Prospectus") and the general information document for investing in public offer ("GID") undertaken through the Book Building Process before applying in the Offer (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference. You may also download the RHP from the website of the Book Running Lead Manager ("BRLM") at www.vivro.net and from the website of the Company at www.fabtechcleanroom.com. Unless otherwise specified all capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

THIS ABRIDGED PROSPECTUS CONSISTS OF 4 PAGES OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND 8 PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

You may obtain a physical copy of the Bid-cum-Application Form and the RHP from stock exchange, syndicate member, registrar to issue, investors' association of Self Certified Syndicate Banks. You may also download the RHP from the websites of Securities and Exchange Board of India ("SEBI"), BRLM and BSE Limited ("Stock Exchange" or "BSE") that is www.sebi.gov.in, www.vivro.net and www.bseindia.com.

Fabtech

FABTECH TECHNOLOGIES CLEANROOMS LIMITED

CIN: U74999MH2015PLC265137 **Date of Incorporation:** June 3, 2015

REGISTERED OFFICE	CONTACT PERSON	TELEPHONE AND EMAIL	WEBSITE
615, Janki Center, Off. Veera Desai Road, Andheri West, Mumbai 400053, Maharashtra, India.	Kinjal Nitinkumar Shah *Company Secretary and Compliance Officer*	**Telephone No:** +91-22 45145321 **Email Id**: secretarial@fabtechnologies.com	www.fabtechcleanroom.com

PROMOTERS OF OUR COMPANY: AASIF AHSAN KHAN, AARIF AHSAN KHAN, HEMANT MOHAN ANAVKAR AND MANISHA HEMANT ANAVKAR

DETAILS OF THE ISSUE TO THE PUBLIC

Type	Fresh Issue Size	Offer for Sale Size	Total Issue Size	Eligibility	Equity Shares Reservation				Employee Reservation Portion
					QIBs	NIIs	RIIs	Market Maker	
Fresh Issue	Up to 32,64,000 Equity Shares of face value of ₹10/- each aggregating to ₹ [•] lakhs	Nil	Up to 32,64,000 Equity Shares of face value of ₹10/- each aggregating to ₹ [•] lakhs.	The Issue is being made pursuant to Regulation 229(2) of Chapter IX of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended ("**SEBI ICDR Regulations**"). As the Company's post issue paid up capital is more than ₹1,000.00 Lakhs and up to ₹2,500.00 Lakhs.	Not more than [•] Equity Shares	At least [•] Equity Shares	At least [•] Equity Shares	Up to [•] Equity shares	NA

These equity shares are proposed to be listed on SME Platform of BSE Limited (i.e. BSE SME). For the purpose of the Issue, the Designated Stock Exchange will be BSE.

DETAILS OF OFS BY PROMOTER(S)/ PROMOTER GROUP/ OTHER SELLING SHAREHOLDERS:

Name	Type	No of Shares offered/ Amount in ₹	WACA in ₹ per Equity	Name	Type	No of Shares offered/ Amount in ₹	WACA in ₹ per Equity
NOT APPLICABLE AS THE ENTIRE ISSUE CONSTITUTES FRESH ISSUE OF EQUITY SHARES							

ELIGIBLITY FOR THE ISSUE
Whether the company is compulsorily required to allot at least 75% of the net offer to public, to qualified institutional buyers - Not Applicable

PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES	
Price Band*	For details of price band and minimum bid lot size, please refer to price band advertisement to be published on December 30, 2024 in all editions of English National Newspaper "Financial Express", all editions of Hindi National Newspaper "Jansatta" and mumbai edition of Mumbai Laksdweep (A widely circulated regional newspaper, (Marathi) regional language of maharastra where our Registered Office is located). Details about the basis of the Issue Price will be available on the website of BSE Limited.
Minimum Bid Lot Size	
Anchor Investor Bidding Date	Thursday, January 2, 2025
Bid/Issue Opens On**	Friday, January 3, 2025
Bid/Issue Closes On***	Tuesday, January 7, 2025
Finalisation of Basis of Allotment with BSE (T+1)	On or about Wednesday, January 8, 2025
Initiation of Refunds (T+2)	On or about Thursday, January 9, 2025
Credit of Equity Shares to Demat accounts of Allottees (T+2)	On or about Thursday, January 9, 2025
Commencement of trading of Equity Shares on BSE (T+3)	On or about Friday, January 10, 2025

**For details of price band and basis of issue price, please refer to price band advertisement and page 266 of the RHP.*

***Our Company may, in consultation with the BRLM, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date i.e.,Thursday, January 2, 2025.*

****Our Company, may, in consultation with the BRLM, consider closing the Bid/ Issue Period for QIBs one day prior to the Bid/ Issue Closing Date in accordance with the SEBI ICDR Regulations.*

-UPI mandate end time and date shall be at 5.00 p.m. on Bid/Issue Closing Date.

DETAILS OF WEIGHTED AVERAGE COST OF ACQUISITION OF ALL SHARES TRANSACTED IN THREE YEARS, EIGHTEEN MONTHS AND ONE YEAR IMMEDIATELY PRECEDING THE RED HERRING PROSPECTUS

Period	Weighted Average Cost of Acquisition (in ₹)*#	Cap Price is 'X' times the Weighted Average Cost of Acquisition^	Range of acquisition price: Lowest Price –Highest Price (in ₹)
Last one year, eighteen months and three years	70.66	1.20	56.00-71.66

**The weighted average cost of acquisition of Equity Shares by our Promoters has been calculated by taking into account the amount paid by them to acquire and Equity Shares allotted to them as reduced by the amount received on sell of Equity Shares i.e. net of sale consideration is divided by net quantity of Equity Shares acquired.*
^As certified by M/s. Ajmera & Ajmera, Chartered Accountants, by way of their certificate dated December 27, 2024.
 # After giving effect of bonus issue in ratio of 2:1.
^ to be updated upon finalization of the Price Band.

*The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended **("Securities Act")** or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur.*

RISKS IN RELATION TO FIRST ISSUE

This being the first Public Issue of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is ₹10/- each. The Floor Price, the Cap Price and the Issue Price (determined by our Company in consultation with the Book Running Lead Manager on the basis of the assessment of market demand for our Equity Shares by way of the Book Building Process as stated under chapter titled "*Basis for Issue Price*" on page 97 of the Red Herring Prospectus), should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investment in equity and equity related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and the Issue including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("**SEBI**") nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of investors is invited to the section titled '*Risk Factors' on* page 29 of the Red Herring Prospectus and on page 9 of this Abridged Prospectus.

PROCEDURE

You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the stock exchange, syndicate member, registrar to the issue, registrar and share transfer agents **("RTA")**, depository participants, stock brokers, underwriter, banker to the issue, investors' associations or Self Certified Syndicate Banks. You may also download the Red Herring Prospectus from the websites of SEBI, Book Running Lead Manager, the Company and Stock Exchange where the equity shares are proposed to be listed that is www.sebi.gov.in, www.vivro.net, www.fabtechcleanroom.com and www.bsesme.com/#publicissues.

If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the RHP and/or the GID from the BRLM or download it from the website of the BRLM at www.vivro.net and the Stock Exchange i.e. www.bsesme.com/#publicissues.

PRICE INFORMATION OF BRLM

Price information of past issues (during the current Financial Year and two Financial Years preceding the current Financial Year) handled by Vivro Financial Services Private Limited

Sr. No.	Issuer Name	Issue Size (in Cr.)	Issue Price (in ₹)	Listing Date	Opening Price on Listing Date (₹)	% Change in closing price, (% change in closing benchmark) - 30th calendar day from listing	% Change in closing price, (% change in closing benchmark) - 90th calendar day from listing	% Change in closing price, (% change in closing benchmark) - 180th calendar day from listing
1	Ganesh Infraworld Limited	98.57	83/-	December 06, 2024	157.70	Not Applicable	Not Applicable	Not Applicable
2	Shiv Texchem Limited	101.35	166/-	October 15, 2024	239.00	+57.95% [-5.05%]	Not Applicable	Not Applicable
3	Bondada Engineering Limited	42.72	75/-	August 30, 2023	142.50	+123.07% [+0.65%]	+492.33% [+1.36%]	+1,114.73% [+12.38%]

Source: Price Information www.bseindia.com and www.nseindia.com and Issue Information from Prospectus of respective companies.

Note:

1. *BSE SENSEX and Nifty 50 is considered as the Benchmark Index.*
2. *"Issue Price" is taken as "Base Price" for calculating % Change in Closing Price of the respective Issues on 30th/90th/180th Calendar days from listing.*
3. *"Closing Benchmark" on the listing day of script is taken as "Base Benchmark" for calculating % Change in Closing Benchmark on 30th/90th/180th Calendar days from listing. Although it shall be noted that for comparing the script with Benchmark, the +/- % Change in Closing Benchmark has been calculated based on the Closing Benchmark on the same day as that of calculated for script in the manner provided in Note No. 4 below.*
4. *In case 30th/90th/180th day is not a trading day, closing price on BSE of the previous trading day for the script has been considered, however, if script is not traded on that previous trading day then last trading price has been considered.*

Name of BRLM and contact details (telephone and email id) of BRLM	**Vivro Financial Services Private Limited** **Telephone:** +91-22 6666 8040 **Email ID:** investors@vivro.net **Investor Grievance ID:** investors@vivro.net

Name of Syndicate Member	**Vivro Financial Services Private Limited**
Name of Market Maker	**Rikhav Securities Limited**
Name of Registrar to the Issue and contact details (telephone and email id)	**Maashitla Securities Private Limited** **Telephone:** + 91-11 4758 1432 **E-mail:** ipo@maashitla.com **Investor Grievance ID:** investor.ipo@maashitla.com
Name of Statutory Auditor	**Ajmera & Ajmera**
Name of Monitoring Agency	As the Net Proceeds of the Issue will be less than ₹10,000 lakhs, under the SEBI ICDR Regulations, our Company is not required to appoint a monitoring agency for the purpose of the Issue.
Name of Credit Rating Agency and the rating or grading obtained, if any	As this is an Issue of Equity Shares, credit rating is not required
Name of Debenture trustee, if any.	As this is an Issue of Equity Shares, the appointment of debenture trustees is not required.
Self-Certified Syndicate Banks	The list of banks that have been notified by SEBI to act as SCSBs for the ASBA process is provided on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35. or at such other website as may be prescribed by SEBI and updated from time to time. A list of the Designated Branches of the SCSBs with which an ASBA Bidder (other than UPI Bidders using the UPI Mechanism), not bidding through Syndicate/ Sub Syndicate or through a Registered Broker, RTA or CDP may submit the Bid cum Application Forms, is available at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 or at such other websites as may be prescribed by SEBI from time to time.
SCSBs eligible as Issue Banks for UPI	In accordance with SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated September 28, 2019, SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022, UPI Bidders using the UPI Mechanism may only apply through the SCSBs and mobile applications whose names appears on the website of the SEBI, which may be updated from time to time. A list of SCSBs and mobile applications, which are live for applying in public issues using UPI Mechanism is provided as 'Annexure A' for the SEBI circular number SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 and is also available on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 for SCSBs and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43 for mobile applications or at such other websites as may be prescribed by SEBI from time to time.
Non-Syndicate Registered Brokers	Bidders can submit ASBA Forms in the Issue using the stockbroker network of the stock exchange, i.e., through the Registered Brokers at the Broker Centres. The list of the Registered Brokers eligible to accept ASBA Forms from Bidders (other than UPI Bidders), including details such as postal address, telephone number and e-mail address, is provided on the websites of the BSE i.e. (www.bseindia.com). For further details, see section titled "*Issue Procedure*" beginning at page 277 of the RHP
Details regarding website address(es)/link(s) from which the investor can obtain list of registrar to issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	The Details of the Designated Registrar and Share Transfer Agents locations and Designated Collecting Depository Participant Locations along with their Names and Contact Details are available on the website of BSE (www.bseindia.com).

PROMOTERS OF THE COMPANY

Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification of Individual promoters
1	Aasif Ahsan Khan	Individual	Aasif Ahsan Khan is Chairman and Non-Executive Director of our Company. He attended the course for diploma degree in Mechanical Engineering from Board of Technical Examination, Maharashtra. He has been associated with our Company as a shareholder and Promoter since 2021. He possesses over three decades of experience in the field of cleanrooms and biopharmaceutical engineering space. He plays a key role in our strategic decision-making processes and is responsible for fostering future growth. In recognition of his contributions as a trainer in the pharmaceutical industry, the Saudi Industrial Development Fund awarded him a certificate of appreciation. Additionally, he received the Shivprabha Jeevan Gaurav Award in 2018 from Shivprabha Charitable Trust.
2	Aarif Ahsan Khan	Individual	He was associated with Fabtech Technologies International Limited from August 2001 to March 2022 in the capacity of Promoter and Director, wherein he played a crucial role in overseeing the production and other factory activities
3	Hemant Mohan Anavkar	Individual	He attended the course for a Diploma in Mechanical Engineering from Board of Technical Examinations, Maharashtra State. He is associated with Fabtech Technologies Limited (formerly known as Fabtech Technologies Private Limited) as a Whole time Director
4	Manisha Hemant Anavkar	Individual	She has been associated with Fabtech Technologies Limited (formerly known as Fabtech Technologies Private Limited) since April 2021 as the Administrative Head of the Company where she plays a crucial role in in overseeing the administrative activities of the company

For details in respect of the Promoters, please see the section entitled titled *"Our Promoters and Promoters Group"* on page 178 of the RHP.

BUSINESS OVERVIEW AND STRATEGY

Company Overview: The issuer is engaged in the business of manufacturing and providing design-to-validation solutions of pre-engineered and pre-fabricated modular panels and doors for building cleanrooms for pharmaceutical, healthcare & biotech sectors. Cleanrooms are specially designed or constructed with a controlled environment to ensure low levels of pollutants, dust, airborne microbes, aerosol and chemical vapor. Our cleanroom solutions, which are tailor made as per our customers' designs and global regulatory standards, comprises of wall panels, view panels, doors, risers, ceiling panels, covings, heat ventilation air conditioning ("**HVAC**") system, epoxy flooring and electrification works. We provide a comprehensive service which includes initial design to validation, encompassing engineering, manufacturing, quality assurance, timely delivery, installation, commissioning, and validation and certification.

Product/Services offerings: manufacturing and providing design-to-validation solutions of pre-engineered and pre-fabricated modular panels and doors for building cleanrooms for pharmaceutical, healthcare & biotech sectors. Cleanrooms are specially designed or constructed with a controlled environment to ensure low levels of pollutants, dust, airborne microbes, aerosol and chemical vapor. For further details, see "Our Business -Overview" on page 136 of the RHP.

Geographies Served:

Domestic and Export Sale

The Company primarily focuses on domestic market and industries. However, the Company has exported to countries such as UAE and Kenya. Revenue breakup based on domestic and export sales for the last three years is as follows:

Particulars	Six months period ended September 30, 2024		FY 23-24	
	Amount (₹ in lakhs)	% of our revenue from operations	Amount (₹ in lakhs)	% of our revenue from operations
Domestic Sales	**5,882.37**	**94.98%**	**9,522.46**	**97.78%**
Export Sales	**310.58**	**5.02%**	**216.69**	**2.22%**
Total Revenue from Operation	**6,192.95**	**100.00%**	**9,739.15**	**100.00%**

Particulars	FY 22-23		FY 21-22	
	Amount (₹ in lakhs)	% of our revenue from operations	Amount (₹ in lakhs)	% of our revenue from operations
Domestic Sales	12,402.05	99.48%	11,297.92	99.37%
Export Sales	64.58	0.52%	71.98	0.63%
Total Revenue from Operation	**12,466.63**	**100.00%**	**11,369.89**	**100.00%**

Following table shows distribution of our revenue from operations on basis of geographical segments :

The table below set out details of our sector wise revenue from operations:

Particulars	As on September 30, 2024		FY 2023-24	
	Amount (₹ in lakhs)	% of our revenue from operations	Amount (₹ in lakhs)	% of our revenue from operations
Pharmaceuticals, Healthcare and Biotech	5,313.36	85.80%	9,258.99	95.07%
Others	879.59	14.20%	480.16	4.93%
Total Revenue from Operations	**6,192.95**	**100.00%**	**9,739.15**	**100.00%**

Particulars	FY 2022-23		FY 2021-22	
	Amount (₹ in lakhs)	% of our revenue from operations	Amount (₹ in lakhs)	% of our revenue from operations
Pharmaceuticals, Healthcare and Biotech	11,763.59	94.36%	10,988.88	96.65%
Others*	703.04	5.64%	381.01	3.35%
Total Revenue from Operations	**12,466.63**	**100.00%**	**11,369.89**	**100.00%**

**includes semiconductors, automobiles, renewable energy, data centres, food and dairy, laboratories, aeronautics and hospitals etc. As the individual contribution per sector is negligible, all such sectors are grouped and disclosed as "Others".*

Key Performance Indicators

Sr. No.	Particulars	Six months period ended September 30, 2024	Fiscal 2024	Fiscal 2023	Fiscal 2022
1	Revenue from Operations (₹ in lakhs)	6,192.95	9,739.15	12,466.63	11,369.89
2	Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) (₹ in lakhs) (1)	754.40	905.81	1,319.94	634.25
3	EBITDA Margins (%)(2)	12.12%	9.24%	10.55%	5.57%
4	Profit after Tax (PAT) (₹ in lakhs)	540.18	578.46	796.28	360.02
5	PAT Margins (%)(3)	8.68%	5.90%	6.37%	3.16%
6	Cash Profit after Tax (₹ in lakhs) (4)	570.23	628.01	849.03	418.03
7	Current Ratio(5)	2.80	2.35	2.27	1.80
8	Debt-Equity Ratio(6)	0.05	0.11	0.13	0.23
9	Return on Equity (%)(7)	9.53%^	11.96%	19.27%	10.10%
10	Return on Capital Employed (%)(8)	11.85%^	15.83%	26.18%	13.27%

^Not Annualized, hence not comparable

***Note:-** For the purpose of the above calculation, "Adjusted Net-worth" is the total value of equity share capital, reserves and surplus excluding the amount of capital reserve and deferred tax assets. As certified by our statutory auditors M/s. Ajmera & Ajmera, Chartered Accountants vide their certificate dated December 26, 2024.*

Notes:

1. *EBITDA has been calculated as a sum of profit before tax, finance costs and depreciation and amortization.*
2. *EBITDA Margins is calculated as EBITDA divided by total income.*
3. *PAT Margins (%) is calculated as Profit After Tax carried to balance sheet divided by Total Income.*
4. *Cash Profit After Tax is calculated as a sum of Profit After Tax to balance sheet and Depreciation and Amortisation as per Restated Consolidated Financial Statements.*

5. *Current Ratio is calculated as Total Current Assets divided by Total Current Liabilities.*
6. *Debt-Equity Ratio is calculated as Total Debt divided by Adjusted Net-Worth as per Restated Consolidated Financial Statements. Total Debt is calculated as a sum of Long-Term Borrowings and Short-Term Borrowings (including current maturity of long-term borrowings).*
7. *Return on Equity is calculated as Restated profit after tax After Tax carried to balance sheet for the year divided by average net worth, where average net worth is calculated by dividing sum of closing adjusted net worth of the current fiscal year and closing adjusted net worth of the previous fiscal year by 2. Adjusted net worth of FY 2021 is taken from audited consolidated financial statements*
8. *Return on Capital Employed is calculated as Earnings Before Interest and Tax divided by Average Capital Employed. Average Capital Employed is calculated by dividing sum of closing capital employed of the current fiscal year and closing capital employed of the previous fiscal year by 2. Capital employed is calculated as sum of adjusted net worth (i.e excluding deferred tax assets and capital reserve), Long-Term Borrowings and short-term borrowings. Capital Employed of FY 2021 is taken from audited consolidated financial statements.*

Industries Served: The end users of the Indian Cleanroom Technologies market include industries such as Pharmaceutical, Semiconductor and Electronic, Biotechnology, Foods and Beverage, Hospital and Healthcare, and others (including Automotive, Plastic, Optical, etc). *(Source : CareEdge Report)*

For further details, please see "Our Business – Our Strategy" on page 140 of the RHP

Revenue segmentation in terms of top clients:

Below are the details of revenue from top 1, 3, 5 and 10 customer for last 3 financial year and the six months period ended September 30, 2024:

Sr. No.	Particulars	Six months period ended September 30, 2024		FY 2023-24	
		Amount (₹ in lakhs)	% of our revenue from operations	Amount (₹ in lakhs)	% of our revenue from operations
1.	Revenue from top one (1) customer	733.64	11.85%	1,876.37	19.27%
2.	Revenue from top three (3) customers	1,854.21	29.94%	3,302.45	33.91%
3.	Revenue from top five (5) customers	2,358.81	38.09%	4,122.39	42.33%
4.	Revenue from top ten (10) customers	3,281.37	52.99%	5,290.77	54.32%

Sr. No.	Particulars	FY 2022-23		FY 2021-22	
		Amount (₹ in lakhs)	% of our revenue from operations	Amount (₹ in lakhs)	% of our revenue from operations
1.	Revenue from top one (1) customer	1,117.41	8.96%	1,811.33	15.93%
2.	Revenue from top three (3) customers	2,567.62	20.60%	3,192.01	28.07%
3.	Revenue from top five (5) customers	4,232.35	33.95%	4,097.34	36.04%
4.	Revenue from top ten (10) customers	6,539.95	52.46%	5,597.49	49.23%

Note: We are unable to disclose the names of individual customers since this information is commercially sensitive to our business.

Intellectual Property, if any:

As on the date of the Red Herring Prospectus, Our Company has currently made the following applications for name change and registration of the trademark in the name of the Company under the Trademarks Act, 1999:

Date of Issue Trademark	Description	Trademark Holder	Trademark Number	Class	Trademark
July 30, 2024	Certificate of Registration under the Trademarks Act, 1999	Fabtech Technologies International Private Limited	6551061	11	FABTECH
July 30, 2024	Certificate of Registration under the Trademarks Act, 1999	Fabtech Technologies International Private Limited	6551062	35	FABTECH
July 30, 2024	Certificate of Registration under the Trademarks Act, 1999	Fabtech Technologies International Private Limited	6551063	37	FABTECH
July 30, 2024	Certificate of Registration under the Trademarks Act, 1999	Fabtech Technologies International Private Limited	6551064	9	FABTECH
July 30, 2024	Certificate of Registration under the Trademarks Act, 1999	Fabtech Technologies International Private Limited	6551065	42	FABTECH

Our Company has also registered the 'https://www.fabtechcleanroom.com/' domain name on which we host our website.

For further information on the intellectual property of our Company, see "*Government and Other Statutory Approvals*" on page 245 and Risk Factors on page 29 of the Red Herring Prospectus.

Market Share: Not ascertainable

Manufacturing plant, if any: Our manufacturing facility is located at Umbergaon, Valsad, Gujarat with a total area of about 70,000 sq. ft.

Employee Strength : As of November 30, 2024, our Company had 117 permanent employees. For further details, please see *"Our Business – Human Resources"* on page 151 of the RHP.

BOARD OF DIRCTORS

Sr. No.	Name	Designation (Independent / Whole time / Executive / Nominee)	Experience & Educational Qualification	Other Directorships
1	Aasif Ahsan Khan	Chairman and Non-Executive Director	Aasif Ahsan Khan attended the course for diploma degree in Mechanical Engineering from Board of Technical Examination, Maharashtra. He has been associated with our Company as a shareholder and Promoter since 2021. He possesses over three decades of experience in the field of cleanrooms and biopharmaceutical engineering space. He plays a key role in our strategic decision-making processes and is responsible for fostering future growth. In recognition of his contributions as a trainer in the pharmaceutical industry, the Saudi Industrial Development Fund awarded him a certificate of appreciation. Additionally, he received the Shivprabha Jeevan Gaurav Award in 2018 from Shivprabha Charitable Trust	*Indian Companies:* 1. Fabtech Technologies International Private Limited 2. Fillpac Solutions Private Limited 3. Podtech Lifesciences Private Limited 4. Alanar Alternative Investment Management Private Limited *Foreign Companies:* 1. G7 Universal LLC

Sr. No.	Name	Designation (Independent / Whole time / Executive / Nominee)	Experience & Educational Qualification	Other Directorships
2	Ausaf Ahmed Usmani	Whole Time Director	Ausaf Ahmed Usmani has been associated with our Company since February 2020. He has vast experience of more than a decade in the field of engineering and sales sectors and other strategic matters. He has played a pivotal role in expanding and diversifying the business operations of our Company.	*Indian Companies:* NIL *Foreign Companies:* NIL
3	Amjad Adam Arbani	Executive Director and Chief Financial officer	Amjad Adam Arbani has been associated with our Company since April 2021 where he overlooked financial operations of our Company. Later he was appointed as the Executive Director w.e.f. June 13, 2024. He looks after the banking relations and legal affairs of the Company.	*Indian Companies:* 1. "T" Square Enterprises Private Limited 2. Channel U Entertainment Private Limited 3. Fabsafe Technologies Private Limited. 4. Advantek Air Systems Private Limited. 5. Buildmighty Techno Private Limited . 6. Fabtech Technologies Limited *Foreign Companies:* NIL
4	Chirag Himatlal Doshi	Non-Executive Director	Chirag Himatlal Doshi, aged 42 years, is a member of the Institute of Chartered Accountants of India. He has previously worked as an ABAS Senior at Lovelock & Lewes from the year July 2004 to November 2007. Further, he was appointed as a Manager, Financial Audit at Siemens Corporate Finance Private Limited from the year November 2007 to February 2009. He is a director on the board of Energize Management Private Limited; Sejal Glass Limited; Ditya Finance Private Limited; CD Letsconnect Experts Private Limited; and Fabtech Technologies Cleanrooms Private Limited. He is a designated partner of CD Financial ReEngineering Advisors LLP, which is engaged in the business of offering financial and business advisory. He holds an experience of more than five years in financial and business consultancy.	*Indian Companies:* 1. Fabtech Technologies Limited 2. Energize Management Private Limited 3. Sejal Glass Limited 4. CD Letsconnect Experts Private Limited. 5. Ganware Hi- Tech Flims Limited *Foreign Companies:* NIL
5	Rupal Dhiren Haria	Non-Executive Independent Director	Rupal Dhiren Haria holds a bachelor's degree in commerce from University of Mumbai. She is also the fellow member of The Institute of Chartered Accountants of India since 1999. She is currently a partner in Atul C Bheda and Company, Chartered Accountants. She has been associated with our Company since 2024.	*Indian Companies:* 1. Livint Technologies Private Limited 2. Ganesh Infraworld Limited *Foreign Companies:* NIL
6	Shyam Nagorao Khante	Non-Executive Independent Director	Shyam Nagorao Khante holds a master's degree in Pharmacy and a diploma in Business Management from Nagpur University. He is a member of The Indian Pharmaceutical Association and is a registered Pharmacist under the Maharashtra State Pharmacy Council. Previously, he served as a director at Amarant Lifesciences Private Limited and is currently a Professor at Poona College of Pharmacy. Since September 2016, he has been associated with RedLotus Pharmtech Private Limited as President. He has been associated with our Company since 2024.	*Indian Companies:* 1. Fabtech Technologies Limited 2. Gansons Private Limited *Foreign Companies:* NIL

For further details in relation to our Board of Directors, see "Our Management" beginning on page 163 of the RHP.

OBJECTS OF THE ISSUE

Issue Proceeds

The details of the Issue Proceeds are set forth in the table below: *(₹ in lakhs)*

Particulars	Amount
Gross Proceeds from this Issue ^	Up to [●]*
Less: Estimated Issue related expenses*	[●]
Net Proceeds from the Issue (Net Proceeds)*	[●]

***to be finalized upon determination of the Issue Price and updated in the Prospectus at the time of filing with the RoC.*

The proposed utilisation of the Net Proceeds by our Company is set forth in the following table: *(₹ in lakhs)*

Particulars	Amount which will be financed from Net Proceeds	Proposed schedule for deployment of the Net Proceeds	
		Fiscal 2025	Fiscal 2026
To meet long-term working capital requirements	1,400.00	1,400.00	-
For acquisition of equity shares of Kelvin Air Conditioning and Ventilation Systems Private Limited	550.00	-	550.00
General Corporate Purposes*	[●]	[●]	[●]
Total Net proceeds^	[●]	[●]	[●]

**To be finalized upon determination of the Issue Price and updated in the Prospectus prior to filing with the RoC. The amount utilized for General Corporate Purposes will not exceed 25% of the Gross Proceeds.*

^ Assuming full subscription and subject to finalization of basis of allotment.

Means of Finance

The fund requirements set out above is proposed to be entirely funded from the Net Proceeds, working capital loans from bank and internal accruals. Accordingly, we confirm that there are no requirements to make firm arrangements of finance under Regulation 230(1)(e) of the SEBI ICDR Regulations. In case of shortfall in the Net Proceeds or any increase in the actual utilisation of funds earmarked for the Objects, our Company may explore a range of options including utilizing our internal accruals, any additional equity and/or debt arrangements.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years: Not Applicable

Name of monitoring agency, if any – Not Applicable

Terms of Issuance of Convertible Security, if any - Not Applicable

SHAREHOLDING PATTERN

Sr. No.	Particulars	Pre-Issue number of shares	% Holding of Pre issue
1.	Promoters and Promoter Group	84,27,450	93.07%
2.	Public	6,27,912	6.93%
	Total	**90,55,362**	**100.00%**

Number/amount of equity shares proposed to be sold by selling shareholders, if any. – Not Applicable

RESTATED CONSOLIDATED FINANCIAL STATEMENTS

(₹ in lakhs, except ratios and per share data)

Particulars	September 30, 2024	March 31, 2024	March 31, 2023	March 31, 2022
Total revenue (including other Income)	6,222.89	9,799.26	12,510.15	11,394.85
Net Profit / (Loss) before tax and extraordinary items	704.48	753.03	1,154.89	513.88
Net Profit / (Loss) after tax and extraordinary items (1)	540.18	578.46	796.28	360.02
Share Capital	905.54	278.59	278.59	278.59
Reserves and Surplus	5,299.93	4,886.69	4,275.41	3,479.13
Adjusted Net worth(2)	6,187.78	5,145.17	4,530.25	3,734.76
Basic/Diluted earnings per share (₹)* (3)	6.00^	6.92	9.53	4.31
Net Asset value per Equity Shares (in ₹)(4)	68.33	61.56	54.20	44.69
Return on Net Worth (%)(5)	9.53%^	11.96%	19.27%	10.10%

^Not Annualized, hence not comparable

Notes:

1) *Profit/(loss) after tax means profit for the year after tax carried to balance sheet after share in profit of associate and excluding minority interest*
2) *Adjusted Net worth means the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.*
3) *Earnings per share are computed in accordance with AS 20 – Earnings per Share (as amended). The EPS as disclosed hereinabove is after giving effect of bonus shares allotted in ratio of 2:1 on June 27, 2024.*
4) *Net Asset Value per Equity Share represents adjusted net worth as at the end of the fiscal year, as divided by the number of Equity Shares as at the end of the fiscal year*
5) *Return on Net worth is calculated as Restated profit after tax After Tax carried to balance sheet for the year divided by average net worth, where average net worth is calculated by dividing sum of closing adjusted net worth of the current fiscal year and closing adjusted net worth of the previous fiscal year by 2. Adjusted net worth of FY 2021 is taken from audited consolidated financial statements.*

INTERNAL RISK FACTORS

The below mentioned risks are top 5 risk factors as per the RHP. For further details, see *"Risk Factors"* on page 29 of the RHP.

1. We have experienced negative cash flows in the prior periods.
2. We have certain contingent liabilities which may adversely affect our financial condition.
3. Majority of our customers operate in the pharmaceuticals, healthcare and biotech sectors. Factors that adversely affect these sectors or capital expenditure by companies within these sectors may adversely affect our business, results of operations and financial condition
4. We require certain approvals and licenses in the ordinary course of business. Any failure to successfully obtain/renew/update such registrations may adversely affect our operations, results of operations and financial condition
5. We propose to utilize a part of the Net Proceeds to undertake proposed acquisition of the equity shares of Kelvin Air Conditioning and Ventilation Systems Private Limited
6. We may in the future continue to make strategic acquisitions to grow our business and further diversify product and service offerings. Our acquisitions are subject to various risks, including risks relating to the integration of these acquired businesses with our existing operations. An inability to identify, complete and successfully integrate such acquisitions could adversely affect our business prospects, results of operations and financial condition
7. We are dependent on limited number of suppliers for supply of key raw materials and we have not made any long term supply arrangement with our suppliers. In an eventuality where our suppliers are unable to deliver us the required materials in a time-bound manner it may have a material adverse effect on our business operations and profitability.
8. Our Company's logo is not registered as on date of Red Herring Prospectus. We may be unable to adequately protect our intellectual property. Furthermore, we may be subject to claims alleging breach of third-party intellectual property rights
9. The Net Proceeds from the Issue are proposed to be deployed by our Company to fund the consideration for the proposed acquisition. If the proposed acquisition is not completed, the proceeds of the Issue will be retained by our Company and used for other objects
10. Our funding requirements and the proposed deployment of Net Proceeds are not appraised by any independent agency and deployment of funds raised through this Issue shall not be subject to monitoring by any monitoring agency

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTIONS

A. A summary of outstanding litigation proceedings as on the date of the Red Herring Prospectus as disclosed in the section titled *"Outstanding Litigation and Material Developments"* on page 238 of the RHP in terms of the SEBI ICDR Regulations is provided below:

Name of Entity	Criminal Proceeding	Tax Proceeding	Statutory or Regulatory Proceeding	Material Civil Litigation	Aggregate amount involved
Company					
By our Company	Nil	NA	NA	Nil	Nil
Against our Company	1	3	Nil	Nil	3.15
Directors (Other than Promoter)					
By our Director	2	NA	NA	1	52.74
Against our Director	1	1	Nil	1	792.56
Promoter					
By our Promoter	Nil	NA	NA	1	Unquantifiable
Against our Promoter	1	Nil	Nil	1	792.42
Subsidiaries					
By our Subsidiaries	Nil	NA	NA	Nil	Nil
Against our Subsidiaries	Nil	10	Nil	Nil	9.36

Further, except as disclosed in "*Outstanding Litigation and Other Material Developments- Litigation proceedings involving our Group Companies*" on page 242 of the RHP.

B. Brief details of top 5 material outstanding litigations against the Company and amount involved is disclosed below:

1. ***FIR No. 0242/2023 and ECA Case No. 65/ 2023 [Criminal Proceedings]:***

An FIR bearing No. 0242/2023 was filed against Fabtech Technologies Cleanrooms Limited ("**our Company**") and others in Bengaluru City for an accidental death of a worker. The FIR was filed for offences under sections 304(A) read with section 34 of the Indian Penal Code. Pursuant to this FIR an Employee Compensation Act Case bearing No. 65 of 2023 ("**ECA Case**") was also filed by the deceased's family against Our Company and others claiming compensation. However, pursuant to a settlement between the family of the deceased and our Company and other accused, the insurance company from whom Our Company has availed insurance for such situations has paid compensation to the deceased's family. Therefore, the ECA case was transferred to the Lok-Adalat and thereafter disposed vide order dated October 30, 2023. In view of the same FIR filed against our Company and others was also not prosecuted further. However, the FIR still stands open.

C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any – **Nil**

D. Brief details of outstanding criminal proceedings against Promoters is as under**:**

1. ***Fabtech Technologies International Limited & Ors. Vs Pawankumar Ramakrishna Chunduru & Ors. - Criminal Revision Application No. 57 of 2022 IN Criminal Case No. SW/02 of 2022***

Pawan Kumar Ramakrishna ("**Complainant**") filed a Summons Warrant Case bearing number 2 of 2022 against Fabtech Technologies International Limited ("**Accused No. 4**") and its directors before the Ld. Metropolitan Magistrate, 65th Andheri Court, Mumbai by under Sections 419, 420, 406, 465, 467, 471 and 34 read with section 120 (B) of Indian Penal Code ("**Complaint**"). It Is the alleged case of the Complainant that in the year 2013-2014, the Complainant received certain work orders from Rajesh Dokaniya and Shirish Devendra Kejriwal ("**Accused No. 2 and Accused No. 3**") pertaining to HVAC and Clean Room Panel for the pharmaceutical factory/ plant of Brucke Pharma Private Limited ("**Accused No. 1**). It is further the case of the Complainant that he had deposited blank cheques with Accused No. 2 and 3. Thereafter it is alleged that, Aasif Ahsan Khan ("**Accused No. 5**") and Amjad Arani ("**Accused No. 6**") had sold supplied and delivered the goods directly to Accused No. 1 pursuant to which the Accused No. 2 and 3 handed over the said blank cheques to Accused No. 5 and 6. Thereafter, it is alleged that Accused No. 5 and 6 prepared bogus invoices, letters and undertaking to prove the liability and have misused the said security deposit cheques by filing complaint under section 138 of Negotiable Instruments Act, 1881. In view of these allegations, the Complainant has filed the present case under sections 419, 420, 406, 465, 467, 471 and 34 read with section 120 (B) of Indian Penal Code. Thereafter vide order dated December 30, 2021, the Ld. Metropolitan Magistrate, Court at Andheri, Mumbai issued summons against all the Accused. The case is currently pending before the Ld. Metropolitan Magistrate, Court at Andheri, Mumbai.

These allegations are categorically denied by Accused No. 4, 5 and 6. During the trial of the Complaint in Criminal Complaint No. 5774/SS/2017 and 5083/SS/2017, the Complainant and other directors of the company i.e., Centech Engineers Limited, neither raised defence nor even put-up any suggestion during the cross examination of the Complainant that the aforesaid cheques were falsely procured by Accused No. 4, 5 and 6 from Accused No. 2 and 3. In fact the two cases filed under the Negotiable Instruments Act were decided against the Complainant and the Court was pleased to convict the said company i.e., Centech Engineers Limited. and being aggrieved by the order they have preferred appeals against the convictions which are pending.

Therefore, being aggrieved by the issuance of process vide order dated December 30, 2021, the Accused No. 4, 5 and 6 have preferred a Criminal Revision Application No. 57 of 2022 against the order dated December 30, 2021 which is pending before the Court of Sessions, Borivali Division, Goregaon, Mumbai and a stay has been granted by the Court on the order dated December 30, 2021. The matter is currently pending and the next hearing date is January 17, 2025.

ANY OTHER INFORMATION AS PER BRLM/ISSUER: NIL

DECLERATION BY THE COMPANY

We hereby declare that all relevant provisions of the Companies Act, 1956, the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the SEBI, established under Section 3 of the SEBI Act, 1992, as the case may be have been complied with and no statement made in the RHP is contrary to the provisions of the Companies Act, 1956, the Companies Act, 2013, the SEBI, 1992 or rules made or guidelines or regulation issued there under, as the case may be. We further certify that all statements in the RHP are true and correct.